ClinVar Miner

Submissions for variant NM_000448.2(RAG1):c.1566G>T (p.Trp522Cys) (rs193922461)

Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 4
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
GeneDx RCV000519696 SCV000616850 pathogenic not provided 2017-10-20 criteria provided, single submitter clinical testing The W522C variant in the RAG1 gene has been reported previously, along with a second variant, in multiple unrelated individuals with immunodeficiency (Villa et al., 2011; De et al., 2010; Buchbinder et al., 2015). The W522C variant is observed in 28/126314 (0.02%) alleles from individuals of non-Finnish European background, in the ExAC dataset, and no individuals were reported to be homozygous (Lek et al., 2016). The W522C variant is a non-conservative amino acid substitution, which is likely to impact secondary protein structure as these residues differ in polarity, charge, size and/or other properties. This substitution occurs at a position that is conserved across species. Functional studies demonstrated a 42% decrease in recombination activity, assessed by induction of the Ighc locus rearrangements in RAG1 knockout mice, compared to wild type (Lee et al., 2014). Therefore, we interpret W522C as a pathogenic variant.
Invitae RCV000696949 SCV000825533 pathogenic Combined cellular and humoral immune defects with granulomas; Severe combined immunodeficiency, autosomal recessive, T cell-negative, B cell-negative, NK cell-positive 2020-08-25 criteria provided, single submitter clinical testing This sequence change replaces tryptophan with cysteine at codon 522 of the RAG1 protein (p.Trp522Cys). The tryptophan residue is highly conserved and there is a large physicochemical difference between tryptophan and cysteine. This variant is present in population databases (rs193922461, ExAC 0.02%). This variant has also been observed in several individuals affected with atypical SCID/Omenn syndrome (OS) and delayed-onset combined immune deficiency (CID) (PMID: 11133745, 25516070, 24290284, 10701853). This variant has also been observed in an individual affected with midline granulomatous disease (PMID: 20489056). ClinVar contains an entry for this variant (Variation ID: 36710). An experimental study has shown that this missense change results in decreased RAG1 recombinase activity (PMID: 20489056). For these reasons, this variant has been classified as Pathogenic.
OMIM RCV000022745 SCV000044034 pathogenic Combined cellular and humoral immune defects with granulomas 2010-08-26 no assertion criteria provided literature only
Women's Health and Genetics/Laboratory Corporation of America, LabCorp RCV000022745 SCV000053058 likely pathogenic Combined cellular and humoral immune defects with granulomas 2015-10-02 no assertion criteria provided clinical testing The c.1566G>T (p.Trp522Cys) variant involves the alteration of a conserved nucleotide and 4/4 in silico tools predict a pathogenic outcome. The variant is present at a low frequency in the control population (0.01% in ExAC), but has been reported in the literature in patients with granulomatous disease (De Ravin_2010), atypical SCID/OS (Villa_2000, Kwan_2013) and common variable immunodeficiency (Lee_2014, Buchbinder_2014). In vitro analysis showed the variant to result in recombination acitivty that was 50-60% reduced compared to WT (De Ravin_2010, Lee_2014).

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.